publication date: Jan. 31, 2020

Drugs & Targets

Predictive Technology Group and Atrin Pharmaceuticals collaborate on molecular diagnostic oncology development

Predictive Technology Group and Atrin Pharmaceuticals are collaborating to develop molecular diagnostic tools to improve selection of cancer patients who would most benefit from treatment with DNA Damage and Response inhibitors, including Atrin’s and other small molecule ATR inhibitors.

Atrin and Predictive will use Predictive Laboratories’ sequencing capabilities and genomics expertise to identify cancer patients with specific molecular markers that predict the level of clinical response to Atrin’s, and other, targeted therapies. This is intended to improve patient outcomes and help Atrin’s to progress its product pipeline, and upon commercialization, improve on the treatments for women with cancer.

“We see an opportunity to develop a precision medicine approach to address unmet medical needs by combining our state-of-the-art sequencing capabilities, genomics expertise and companion diagnostics with Atrin’s targeted therapeutics,” Bradley Robinson, president and chief executive officer of Predictive Technology Group, said in a statement.

The collaboration will help optimize the safety and clinical efficacy of Atrin’s targeted cancer therapeutics and other DDR drug candidates. Atrin will have access to Predictive’s proprietary GenDB databases and women’s health biobank to better understand the clinical spectrum of germline mutations in DDR pathways. The companies will also study common gynecologic disorders, such as endometriosis, associated with the development of cancers in affected patients. The goal of this collaboration is to develop actionable predictive molecular and companion diagnostics and therapeutics for these common disorders and related cancers.

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.